Anixa Biosciences (ANIX) 10-Q2023 Q2 Quarterly report

Filed: 14 Jun 23, 5:09pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: cell, cohort, higher, successive

Removed: advanced, antiretroviral, area, assay, assignment, bank, behavior, billion, biological, biopsy, chemical, chemistry, combinatorial, comparable, computational, credit, demonstrated, disrupt, Energy, Fluorescence, FRET, function, identification, increased, infected, Initial, key, learning, machine, medicinal, modeling, molecular, monitoring, Mpro, nirmatrelvir, noticeable, optimized, Paxlovid, performing, personnel, platform, potency, potentially, project, proprietary, Remdesivir, Resonance, ritonavir, screening, showed, silico, suggest, synthesized, synthetic, team, utilized, weight

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ANIX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Statement of Chief Financial Officer

Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Michael J. Catelani, the President, Chief Operating Officer and Chief Financial Officer of Anixa Biosciences, Inc., hereby certifies that:

	1.	The Company’s Form 10-Q Quarterly Report for the period ended April 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ Michael J. Catelani
		Michael J. Catelani
		President, Chief Operating Officer and Chief Financial Officer
June 14, 2023		(Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.